HepafleX™
HepafleX™
HepafleX (virginiamycin) Type A medicated article is approved for the reduction of incidence of liver abscesses in cattle fed in confinement.
Key Product Benefits:
- Reduces incidence of liver abscesses
- No withdrawal period is required
- Approved in combination with Rumensin® and Experior®
- Over 26% reduction in incidence of liver abscesses¹
Weight
See Product LabelDosage
See Product Label
Why Control Liver Abscesses?
Liver abscesses cost the US beef industry around $256 million annually with costs attributed to liver and offal condemnation ($72.3 million) and processing speed delays ($11.6 million)2. The hidden cost of liver abscesses lie in excess carcass trim, which are often not reported back to the producer, and are estimated to cost the industry $35.1 million annually3. Liver abscesses also rob feedyard profitability before the processing plant, with studies finding a loss in average daily gain of 5.3 percent (0.17 lb) in animals with A+ liver abscesses4.
Stay connected with HepafleX
Get the latest updates, news and offers from Elanco delivered directly to your inbox.
Directions for Use:
For reduction of incidence of liver abscesses of cattle fed in confinement for slaughter: Feed 85-240 mg/hd/day at 13.5-16.0 g/ton of complete feed (90% dry matter basis).
Important Safety Information:
- Caution: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
- Not for use in animals intended for breeding.
Experior, HepafleX, Optaflexx, Rumensin, and Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. ©2025 Elanco or its affiliates.
